Trial Profile
Pharmacokinetics and Tolerability of Zavesca (Miglustat) In Patients With Juvenile GM2 Gangliosidosis: Single and Multiple Oral Doses
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Miglustat (Primary)
- Indications Gangliosidoses
- Focus Pharmacokinetics
- 31 May 2016 New trial record
- 18 May 2016 Status changed from active, no longer recruiting to completed.